Lexicon Pharmaceuticals (LXRX) Earnings Date, Estimates & Call Transcripts → Urgent Nvidia Warning (From Altimetry) (Ad) Free LXRX Stock Alerts $1.58 +0.04 (+2.60%) (As of 04/26/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateMay. 7EstimatedActual EPS (Mar. 11) -$0.20 Beat By $0.03 Consensus EPS (Mar. 11) -$0.23 Get Lexicon Pharmaceuticals Earnings AlertsEnter your email address below to receive the latest news and earnings results for LXRX and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueLXRX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.LXRX Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad AltimetryUrgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.Click here to access… Lexicon Pharmaceuticals Analyst EPS EstimatesCurrent Year EPS Consensus Estimate:($0.71) EPSNext Year EPS Consensus Estimate: ($0.66) EPSLXRX Earnings Date and InformationLexicon Pharmaceuticals last announced its quarterly earnings results on March 11th, 2024. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.03. The business earned $0.70 million during the quarter, compared to analysts' expectations of $0.68 million. Lexicon Pharmaceuticals has generated ($0.80) earnings per share over the last year (($0.80) diluted earnings per share). Earnings for Lexicon Pharmaceuticals are expected to grow in the coming year, from ($0.71) to ($0.66) per share. Lexicon Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 7th, 2024 based off prior year's report dates.Read More Lexicon Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/7/2024Estimated)------- 3/11/2024Q4 2023($0.23)($0.20)+$0.03($0.20)$0.68 million$0.70 million11/8/2023Q3 2023($0.22)($0.21)+$0.01($0.21)$1.49 million$0.16 million 8/3/2023Q2 2023($0.17)($0.22)($0.05)($0.22)$0.30 million$0.32 million5/2/2023Q1 2023($0.17)($0.17)-($0.17)-$0.02 million3/2/2023Q4 2022($0.14)($0.16)($0.02)($0.16)-$0.03 million11/9/2022Q3 2022($0.15)($0.13)+$0.02($0.13)-$0.04 million Get the Latest News and Ratings for LXRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 8/2/2022Q2 2022($0.15)($0.16)($0.01)($0.16)-$0.04 million5/5/2022Q1 2022($0.16)($0.16)-($0.16)-$0.04 million 2/28/2022Q4 2021($0.17)($0.17)-($0.17)-$0.01 million 11/3/2021Q3 2021($0.18)($0.16)+$0.02($0.16)-$0.02 million 7/30/2021Q2 2021($0.16)($0.13)+$0.03($0.13)$0.03 million$0.23 million 5/6/2021Q1 2021($0.17)($0.15)+$0.02($0.15)$3.35 million$0.03 million Lexicon Pharmaceuticals Earnings - Frequently Asked Questions When is Lexicon Pharmaceuticals's earnings date? Lexicon Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 7th, 2024 based off last year's report dates. Learn more on LXRX's earnings history. Did Lexicon Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Lexicon Pharmaceuticals (NASDAQ:LXRX) reported ($0.20) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.23) by $0.03. Learn more on analysts' earnings estimate vs. LXRX's actual earnings. How much revenue does Lexicon Pharmaceuticals generate each year? Lexicon Pharmaceuticals (NASDAQ:LXRX) has a recorded annual revenue of $1.20 million. How much profit does Lexicon Pharmaceuticals generate each year? Lexicon Pharmaceuticals (NASDAQ:LXRX) has a recorded net income of -$177.12 million. LXRX has generated -$0.80 earnings per share over the last four quarters. What is Lexicon Pharmaceuticals's EPS forecast for next year? Lexicon Pharmaceuticals's earnings are expected to grow from ($0.71) per share to ($0.66) per share in the next year. More Earnings Resources from MarketBeat Related Companies: XOMA Earnings VSTM Earnings VNDA Earnings RIGL Earnings RGLS Earnings RZLT Earnings OPK Earnings INVA Earnings MNKD Earnings IRWD Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NASDAQ:LXRX) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressWhy Big Pharma is Investing Billions in This BiotechBehind the MarketsJeff Bezos Just Humiliated Elon MuskInvestorPlaceThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
